| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 268.9 | 239.5 |
| Gross profit | 188.2 | 179.8 |
| Profit before tax | 59.2 | 67.5 |
| Net income | 48.2 | 50.9 |
| EPS (diluted, $ a share) | $0.81 | $0.87 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -5.2% |
|---|---|
| Revenue, year on year | +12.3% |
| Gross margin | 70.0% |
| Operating margin | 20.2% |
10-Q filed with the SEC, NASDAQ: HRMY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Harmony Biosciences Holdings, Inc.: key numbers
- Share price
- $32.96Close, Nov 16
- Market cap
- $1.94B
- Shares outstanding
- 58.72MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Harmony Biosciences Holdings, Inc.
All →Harmony Biosciences Holdings Financial Results
Harmony Biosciences reported Q3 2026 financial results with WAKIX net revenue of $269 million, driven by 400 net patient additions. The company reaffirmed its full-year 2026 revenue guidance of $1.0 billion to $1.04 billion and announced that Peter Anastasiou will succeed Jeffrey Dayno as CEO effective January 1, 2027.
“As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation, conviction to pursue strategic business development opportunities, and a pipeline led by BP-205 that has the potential to generate significant long-term value.”
Jeffrey Dayno, MD, President and Chief Executive Officer
“I am proud of the talented team and passionate organization we have built, which position Harmony for continued success in delivering innovative treatments to patients and sustained value for our shareholders.”
Jeffrey Dayno, MD, President and Chief Executive Officer
Harmony Biosciences Holdings Executive Compensation
Harmony Biosciences announced the compensation terms for its leadership succession plan, including a separation and consulting agreement for retiring CEO Jeffrey M. Dayno and an amended employment agreement for incoming CEO Peter Anastasiou. Dr. Dayno will serve as a non-executive advisor through January 2028 at a rate of $500 per hour with continued equity vesting, while Mr. Anastasiou's new terms as President and CEO take effect January 1, 2027.
- Term
- through Jan 2028
Harmony Biosciences Holdings Leadership Change
Harmony Biosciences announced that Jeffrey M. Dayno, M.D., will retire as President, CEO, and Director effective December 31, 2026. Peter Anastasiou, the company's current Chief Operating Officer and former board member, has been appointed to succeed him as President, CEO, and Director effective January 1, 2027. Dr. Dayno will remain with the company as a non-executive advisor through 2027 to support the transition.
Harmony Biosciences Holdings CMO Kumar Budur Sells $1.66M of Stock
Kumar Budur, CMO, sold 38,452 shares of Harmony Biosciences Holdings, Inc. at $43.00 to $43.05 a share (average $43.05) in 3 transactions, worth $1.66M in total between Sep 16, 2026 and Sep 18, 2026. Shares held after the trade: 13,115 (-73.2%).
- Value
- $1.66M
- Shares
- 38,452
- Average price
- $43.05
- Role
- CMO
- Holding change
- -73.2%
- Trade date
- Sep 16, 2026 to Sep 18, 2026